Eli Lily: LUCENT 1: Protocol I6T-MC-AMAN:A Phase 3, Multicenter, Randomized, Double-Blind, Parallel,Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis
Ironwood: Protocol C3718-302:A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors
Summit: Ri-CoDIFy: Protocol SMT19969/C005: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment of Clostridium difficile infection (CDI)
Celgene: Yellowstone: Protocol RPC01-3201: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severly Active Crohn’s Disease
Interested in participating in a study?
Get in touch with our research team member, Gigi Willis at 571-535-2587 or submit an online inquiry here https://www.researchascare.com/contact/